Pain Management market Insights: Rising demand for effective pain management solutions across chronic and post-surgical segments propels growth.

AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug ...

Editor’s Note: The Business Journal this week is honoring Gavin Herbert with our first ever Lifetime Achievement Recognition.

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...

ABBV-RGX-314 in Diabetic Retinopathy (DR), Suprachoroidal Delivery AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector ® to ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

In this presentation from OSN New York, Thomas W. Samuelson, MD, of Minnesota Eye Consultants, uses surgical footage to demonstrate implantation of the Xen gel stent for the treatment of glaucoma.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring ...

AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings ...

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting ...